^
BIOMARKER:

HER-2 underexpression

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Phase 1
Bayer
Recruiting
Last update posted :
07/27/2021
Initiation :
07/02/2020
Primary completion :
12/30/2024
Completion :
09/07/2026
HER-2
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
BAY2701438 • BAY2701439
Phase 1b
AstraZeneca
Recruiting
Last update posted :
07/19/2021
Initiation :
12/17/2020
Primary completion :
08/28/2023
Completion :
08/28/2023
HER-2 • ER • PGR
|
HER-2 expression • HER-2 underexpression • PGR positive • PGR negative
|
paclitaxel • Imfinzi (durvalumab) • capecitabine • fulvestrant • Enhertu (fam-trastuzumab deruxtecan-nxki) • capivasertib (AZD5363) • anastrozole
Phase 1
Shanghai Fosun Pharmaceutical Development Co, Ltd.
Recruiting
Last update posted :
07/12/2021
Initiation :
10/11/2019
Primary completion :
09/01/2023
Completion :
06/01/2025
HER-2
|
HER-2 positive • HER-2 overexpression • HER-2 underexpression
|
trastuzumab mafodotin (FS-1502)
Phase 1
Daiichi Sankyo Co., Ltd.
Active, not recruiting
Last update posted :
06/23/2021
Initiation :
09/01/2015
Primary completion :
02/01/2019
Completion :
09/30/2021
HER-2
|
HER-2 positive • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 1b
Daiichi Sankyo, Inc.
Recruiting
Last update posted :
04/30/2021
Initiation :
02/10/2020
Primary completion :
08/01/2022
Completion :
05/01/2023
EGFR • HER-2 • BRAF • ALK • ROS1
|
BRAF V600E • HER-2 positive • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ROS1 fusion • ALK mutation • ALK-ROS1 fusion
|
Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 2
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting
Last update posted :
04/02/2021
Initiation :
07/01/2021
Primary completion :
07/01/2023
Completion :
07/01/2024
HER-2
|
HER-2 overexpression • HER-2 underexpression
Phase 2
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting
Last update posted :
04/01/2021
Initiation :
08/01/2021
Primary completion :
08/01/2024
Completion :
12/01/2024
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
Phase 3
RemeGen
Recruiting
Last update posted :
03/08/2021
Initiation :
09/29/2020
Primary completion :
12/31/2022
Completion :
12/30/2023
HER-2
|
HR positive • HER-2 expression • HER-2 underexpression
|
paclitaxel • docetaxel • capecitabine • vinorelbine tartrate • disitamab vedotin (RC48)
Phase 2
MedSIR
Recruiting
Last update posted :
03/04/2021
Initiation :
05/25/2020
Primary completion :
11/01/2021
Completion :
02/01/2023
HER-2
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
01/12/2021
Initiation :
07/16/2018
Primary completion :
04/01/2021
Completion :
12/01/2021
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
Phase 2
Jenny C. Chang, MD
Withdrawn
Last update posted :
09/14/2016
Initiation :
03/01/2016
Primary completion :
04/01/2019
Completion :
05/01/2019
HER-2
|
HER-2 expression • HER-2 underexpression
|
Kadcyla (ado-trastuzumab emtansine)